The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
Open accessAbstract
The motor symptoms of Parkinson’s disease (PD) are due to the progressive loss of dopamine (DA) neurons in substantia nigra pars compacta (SNc). Nothing is known to slow the progression of the disease, making the identification of potential neuroprotective agents of great clinical importance. Previous studies using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD have shown that antagonism of L-type Ca2+ channels protects SNc DA neurons. However, this was not true in a 6-hydroxydopamine (6-OHDA) model. One potential explanation for this discrepancy is that protection in the 6-OHDA model requires greater antagonism of Cav1.3 L-type Ca2+ channels thought to underlie vulnerability and this was not achievable with the low affinity dihydropyridine (DHP) antagonist used. To test this hypothesis, the DHP with the highest affinity for Cav1.3 L-type channels – isradipine – was systemically administered and then the DA toxin 6-OHDA injected intrastriatally. Twenty-five days later, neuroprotection and plasma concentration of isradipine were determined. This analysis revealed that isradipine produced a dose-dependent sparing of DA fibers and cell bodies at concentrations achievable in humans, suggesting that isradipine is a potentially viable neuroprotective agent for PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 13,417
The efficiency of systematic sampling in stereology and its prediction*
Gundersen, H. J. G., & Jensen, E. B. (1987) · Journal of Microscopy · doi:10.1111/j.1365-2818.1987.tb02837.x · Cited by 3,520
mouse brain in stereotaxic coordinates
Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258
West, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301
‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease
Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., Meredith, G. E., & Surmeier, D. J. (2007) · Nature · doi:10.1038/nature05865 · Cited by 904
Self-citationOxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1
Guzman, J. N., Sanchez-Padilla, J., Wokosin, D., Kondapalli, J., Ilijic, E., Schumacker, P. T., & Surmeier, D. J. (2010) · Nature · doi:10.1038/nature09536 · Cited by 843
Self-citationMcCormack, A. L., Thiruchelvam, M., Manning-Bog, A. B., Thiffault, C., Langston, J. W., Cory-Slechta, D. A., & Di Monte, D. A. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0507 · Cited by 838
Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state.
Bean, B. P. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.20.6388 · Cited by 824
Sauer, H., & Oertel, W. H. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90605-x · Cited by 803
Cited by
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
Self-citationZamponi, G. W., Striessnig, J., Koschak, A., & Dolphin, A. C. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009654 · Cited by 1,103
Disruption of mitochondrial complex I induces progressive parkinsonism
González-Rodríguez, P., Zampese, E., Stout, K. A., Guzman, J. N., Ilijic, E., Yang, B., Tkatch, T., Stavarache, M. A., Wokosin, D. L., Gao, L., et al. (2021) · Nature · doi:10.1038/s41586-021-04059-0 · Cited by 546
Self-citationPacelli, C., Giguère, N., Bourque, M.-J., Lévesque, M., Slack, R. S., & Trudeau, L.-É. (2015) · Current Biology · doi:10.1016/j.cub.2015.07.050 · Cited by 530
A Guide to Neurotoxic Animal Models of Parkinson's Disease
Tieu, K. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009316 · Cited by 483
Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration
Verma, M., Lizama, B. N., & Chu, C. T. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-021-00278-7 · Cited by 451
Determinants of dopaminergic neuron loss in Parkinson's disease
Surmeier, D. J. (2018) · The FEBS Journal · doi:10.1111/febs.14607 · Cited by 444
Self-citationProgress towards therapies for disease modification in Parkinson's disease
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R., & Foltynie, T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00061-2 · Cited by 419
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
Henrich, M. T., Oertel, W. H., Surmeier, D. J., & Geibl, F. F. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00676-7 · Cited by 406
Self-citationNew insights into the complex role of mitochondria in Parkinson’s disease
Grünewald, A., Kumar, K. R., & Sue, C. M. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.09.003 · Cited by 364
Calcium signaling and molecular mechanisms underlying neurodegenerative diseases
Pchitskaya, E., Popugaeva, E., & Bezprozvanny, I. (2018) · Cell Calcium · doi:10.1016/j.ceca.2017.06.008 · Cited by 349
The Role of Oxidative Stress in Parkinson’s Disease
Chang, K.-H., & Chen, C.-M. (2020) · Antioxidants · doi:10.3390/antiox9070597 · Cited by 341
Mitochondria and Parkinson’s Disease: Clinical, Molecular, and Translational Aspects
Borsche, M., Pereira, S. L., Klein, C., & Grünewald, A. (2021) · Journal of Parkinson's Disease · doi:10.3233/jpd-201981 · Cited by 275
The ongoing pursuit of neuroprotective therapies in Parkinson disease
Athauda, D., & Foltynie, T. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.226 · Cited by 269
Surmeier, D. J., Guzman, J. N., Sanchez-Padilla, J., & Schumacker, P. T. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.045 · Cited by 236
Self-citationPillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112275 · Cited by 140
Verma, M., Callio, J., Otero, P. A., Sekler, I., Wills, Z. P., & Chu, C. T. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3791-16.2017 · Cited by 128
Calcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures
Chakroborty, S., & Stutzmann, G. E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.012 · Cited by 91
Striatal glutamatergic hyperactivity in Parkinson's disease
Campanelli, F., Natale, G., Marino, G., Ghiglieri, V., & Calabresi, P. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105697 · Cited by 86
Calcium, Bioenergetics, and Parkinson’s Disease
Zampese, E., & Surmeier, D. J. (2020) · Cells · doi:10.3390/cells9092045 · Cited by 79
Self-citationCronin, A., & Grealy, M. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.10.018 · Cited by 68
Watanabe, H., Dijkstra, J. M., & Nagatsu, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042009 · Cited by 48
Promising therapeutic agents for the treatment of Parkinson’s disease
Majláth, Z., Török, N., Toldi, J., & Vécsei, L. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1164687 · Cited by 7
Wickline, J. L., Smith, S., Shin, R., Odfalk, K., Sanchez, J., Javors, M., Ginsburg, B., & Hopp, S. C. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109454 · Cited by 2
Metadata
- Authors
- Ilijic, E., Guzman, J. N., & Surmeier, D. J.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 43
- Issue
- 2
- Pages
- 364-371
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2010680034
- Cited by
- 259
- References
- 37
- FWCI
- 8.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.